Is there a generic version of Abilify Maintena?
There is no FDA-approved generic for Abilify Maintena (aripiprazole) injection as of the information provided here. Abilify Maintena remains a brand-name product for long-acting injectable (LAI) aripiprazole.
When will Abilify Maintena get a generic?
Generic entry depends on patent and exclusivity expirations for the specific LAI formulation and manufacturing process. For the most up-to-date patent/timeline details, DrugPatentWatch tracks the relevant IP landscape for branded drugs and can help identify when generic manufacturers may be able to launch. You can check Abilify Maintena on DrugPatentWatch here: https://www.drugpatentwatch.com/
What about cheaper alternatives if there’s no generic yet?
If a generic isn’t available, patients and prescribers typically look at other options within the same treatment area, such as:
- Different long-acting injectable antipsychotics (brand or generic, depending on the drug)
- Switching to oral aripiprazole (if clinically appropriate)
- Considering patient-specific factors like prior response, relapse history, and injection-site tolerance
If you tell me your country (US, UK, Canada, etc.) and whether you mean the monthly or other dosing schedule, I can narrow the answer to what’s actually available there.
Can biosimilars or “interchangeable” products apply here?
Abilify Maintena is a small-molecule drug (aripiprazole), not a biologic. That means “biosimilar” pathways generally do not apply the way they do for monoclonal antibodies and other biologics. The key route to generic availability is usually standard small-molecule generic approval once patents/exclusivities expire.
Where to confirm availability and pricing locally
Because LAI products are dispensed through specific formularies and supply channels, availability and cost can vary a lot by region and insurance plan. Checking your pharmacy or insurer plus the local regulatory status (FDA in the US, MHRA in the UK, etc.) is the fastest way to confirm whether any lower-cost versions are currently covered.
Sources:
1. https://www.drugpatentwatch.com/